Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 12/20 | 0.64 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 4/20 | 0.61 |
| ▸ | FLT3 | P36888 | 6/20 | 0.61 |
| ▸ | AXL | P30530 | 2/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.61 |
| ▸ | KIT | P10721 | 1/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.60 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374110 | 0.89 | AXL (0.65) | METPDGFRAKDRFLT3AXL | |
| SCHEMBL374061 | 0.84 | PDGFRA (0.63) | METPDGFRAKDRFLT3AXL | |
| SCHEMBL2744790 | 0.83 | PDGFRA (0.69) | METPDGFRAKDRFLT3AXL | |
| SCHEMBL5056203 | 0.83 | PDGFRA (0.72) | METPDGFRAKDRFLT3AXL | |
| SCHEMBL5052345 | 0.83 | PDGFRA (0.69) | METPDGFRAKDRFLT3AXL | |
| SCHEMBL20096036 | 0.83 | MET (0.72) | METPDGFRAKDRFLT3AXL | |
| SCHEMBL371539 | 0.82 | MET (0.70) | METPDGFRAKDRAXLRET | |
| SCHEMBL19373219 | 0.81 | PDGFRA (0.69) | METPDGFRAKDRFLT3AXL | |
| SCHEMBL29693530 | 0.81 | PDGFRA (0.64) | METPDGFRAKDRFLT3AXL | |
| SCHEMBL407651 | 0.81 | PDGFRA (0.64) | METPDGFRAKDRFLT3AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408300-B1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-05-11 | — | — | EP | disclosed |
| US-8232294-B2 | Amino ester derivatives, sailts thereof and methods of use | Xi, Ning (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2408300-A1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | Sunshine Lake Pharma Co., Ltd (CN) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010111063-A1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | XI NING (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100239576-A1 | AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239576-A1 | AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE | SRC, BCAT1, BCAT2 | MET 185/4885PDGFRA 423/4885KDR 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.